| Journal | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics |
| Study Type | Open-Label Trial |
| Population | Human participants |
This study represents the first systematic investigation of cannabis medicine for PANS, a devastating pediatric condition with limited treatment options. The multi-omics approach provides unprecedented molecular insight into how cannabinoids may modulate immune and epigenetic pathways in neuropsychiatric disorders.
This open-label trial treated 14 children with chronic PANS using 20 mg/kg/day of a cannabinoid-rich, low-THC cannabis extract (NTI164) for 12 weeks. Clinical Global Impression-Severity scores improved significantly from 4.8 to 3.3, indicating meaningful symptom reduction. The researchers employed comprehensive molecular profiling including transcriptomics, proteomics, and DNA methylation analysis to map biological changes. As an uncontrolled study with small sample size, findings require validation through randomized controlled trials before establishing clinical recommendations.
“While the molecular data is fascinating and the clinical improvements encouraging, I remain cautious about drawing practice-changing conclusions from 14 patients in an open-label design. The mechanistic insights into epigenetic modulation are compelling enough to justify larger, controlled studies.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is the recommended dosage of NTI164 for pediatric PANS patients?
The study used 20 mg/kg/day of NTI164, a cannabinoid-rich low-THC cannabis extract, administered over 12 weeks. This dosage was well-tolerated in children aged 4-17 years with chronic-relapsing PANS.
How effective was cannabis treatment for PANS symptoms?
Treatment with NTI164 significantly improved clinical severity scores, decreasing the mean Clinical Global Impression-Severity (CGI-S) score from 4.8 to 3.3 (p = 0.002). The study also demonstrated significant improvements in other clinical measures over the 12-week treatment period.
What are the safety considerations for using cannabis in pediatric PANS patients?
NTI164 was well-tolerated in all 14 children in the study, with no significant adverse events reported. The extract is specifically formulated as a low-THC, cannabinoid-rich preparation to minimize psychoactive effects while maintaining therapeutic benefits.
How does cannabis work to treat PANS at the biological level?
The study showed that NTI164 modifies epigenetic pathways, ribosomal function, and immune system responses through changes in gene expression, protein levels, and DNA methylation. This multi-pathway approach addresses the underlying immune dysfunction and epigenetic dysregulation characteristic of PANS.
Should cannabis be considered as first-line treatment for PANS?
This was a small open-label trial of 14 patients, so larger randomized controlled trials are needed before establishing cannabis as standard treatment. However, the promising results suggest it may be considered for treatment-resistant cases or as part of a comprehensive therapeutic approach for chronic-relapsing PANS.
